Gelonghui, Feb. 4: Yahong Pharmaceutical (688176.SH) announced that recently, a key randomized, double-blind, controlled, multi-center clinical trial of the company's product APL1202 combined with chemotherapy infusion to treat medium- and high-risk non-muscle-invasive bladder cancer (NMIBC) recurrent with chemotherapy perfusion has been completed. Statistical analysis results showed that although showing a certain trend of efficacy among some patients, this study did not reach the main study end point, and the company decided to stop further development of APL-1202 in combination with chemotherapy infusion for this indication.

As of December 31, 2023, a total of about 129.668,600 yuan has been invested in critical clinical trials using APL-1202 and chemotherapy infusion in combination to treat recurrence with chemotherapy perfusion. According to relevant accounting standards and the company's accounting policies, the above R&D expenses are included in the profit and loss of the corresponding accounting period when they are incurred, and will not have a significant impact on the company's current performance.